Is ALNY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Amvuttra ATTR-CM ramp, with total revenue (ttm) at ~$4.8B. The bear case rests on revenue is heavily concentrated in the TTR franchise, and the July 2026 guidance cut showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the total revenue range produced a 28% one-day drop. Analysts covering it are spread from $250.00 to $536.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is heavily concentrated in the TTR franchise, and the July 2026 guidance cut showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the total revenue range produced a 28% one-day drop. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $250.00, +7.8% from the $231.83 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Amvuttra ATTR-CM ramp. The March 2025 approval of Amvuttra for ATTR cardiomyopathy opened a market many multiples larger than its original polyneuropathy indication, and the launch remains the single biggest growth driver: Amvuttra revenue rose 106% to about $1.01 billion in Q2 2026. The most optimistic analyst target on ALNY is $536.00, +131.2% from the $231.83 price. That figure is only reachable if this thesis works close to its best case.

Revenue is heavily concentrated in the TTR franchise, and the July 2026 guidance cut showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the total revenue range produced a 28% one-day drop. The ATTR-CM market is a genuine contest, with Pfizer's entrenched tafamidis (Vyndaqel/Vyndamax), BridgeBio's oral acoramidis (Attruby), and Ionis/AstraZeneca's eplontersen (Wainua) all competing, and new RNAi entrants keep raising capital. Biotech valuations are sensitive to clinical trial outcomes, and pipeline readouts in Alzheimer's and other areas could disappoint. Even after the slide, the stock trades near 40 times trailing earnings, which assumes years of strong growth. Drug pricing pressure, including government price negotiation under the Inflation Reduction Act, and patent or regulatory changes are ongoing overhangs. Debt of about $3.0 billion sits roughly level with the cash balance. The most pessimistic published target is $250.00, +7.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Amvuttra ATTR-CM ramp) stalling in the reported numbers rather than in the narrative, the risk above (revenue is heavily concentrated in the TTR franchise, and the July 2026 guidance cut showed how sensitive the stock is to even a modest change in Amvuttra's trajectory: a roughly 4% trim to the total revenue range produced a 28% one-day drop) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Alnylam develops and sells RNA interference (RNAi) therapeutics, medicines that silence disease-causing genes. Its main products treat TTR amyloidosis (Amvuttra and Onpattro), acute hepatic porphyria (Givlaari), and a rare kidney disorder (Oxlumo). It also earns royalties on Leqvio, an RNAi cholesterol drug sold by Novartis. The company pioneered turning the RNAi mechanism into a repeatable drug-development platform.

Amvuttra (vutrisiran) is Alnylam's largest revenue driver by a wide margin. Its March 2025 FDA approval for ATTR cardiomyopathy expanded it into a much bigger patient population than its original nerve-disease indication. That single approval is the main reason revenue nearly doubled and the company reached profitability. Because so much revenue rests on it, Amvuttra's performance largely defines the investment case. The July 2026 cut to TTR guidance, tied to slower second-line demand, showed how directly Amvuttra's growth rate moves the stock.

Yes. After years of heavy research spending, Alnylam reached both GAAP and non-GAAP profitability for full-year 2025 on roughly $3 billion of net product revenue. It stayed profitable in 2026, with net income of about $206 million in Q1 and about $164 million in Q2, for trailing twelve-month net income near $775 million. Q2 non-GAAP operating income was about $318 million.